In vivo near-infrared fluorescence imaging of integrin α 2β 1 in prostate cancer with cell-penetrating-peptide- conjugated DGEA probe

Journal of Nuclear Medicine

Volumn 52, Issue 12, 2011, Pages 1979-1986

  Huang, Chiun Wei ^a   Li, Zibo ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cell penetrating peptides; Integrin 2 1; Prognostic marker; Prostate cancer

Indexed keywords

CARBOXYPEPTIDASE; CELL PENETRATING PEPTIDE; CELL PENETRATING PEPTIDE CONJUGATED DGEA PEPTIDE DERIVATIVE; DGEA PEPTIDE; FLUORESCENT DYE; GLYCINE; LYSINE; PEPTIDE DERIVATIVE; POLYARGININE PEPTIDE R4 ASPARTYLGLYCYLGLUTAMYLALANINE; POLYARGININE PEPTIDE R4 ASPARTYLGLYCYLGLUTAMYLALANYLGLYCYLLYSYL(N HYDROXYSUCCINIMIDE ESTER); UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FLUORESCENCE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; MALE; MOUSE; NANOPROBE; NEAR INFRARED FLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; FLUORESCENT DYES; HUMANS; INFRARED RAYS; INTEGRIN ALPHA2BETA1; KIDNEY; MALE; MOLECULAR IMAGING; OLIGOPEPTIDES; OPTICAL PROCESSES; PROSTATIC NEOPLASMS;

EID: 83755168263     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.091256     Document Type: Article

References (36)

1. The Surveillance, Epidemiology, and End Results Program: cancer of the prostate statistics 2010. National Cancer Institute Web site. Available at: http://seer.cancer.gov/statfacts/html/prost.html. Accessed October 19, 2011.
2. Pashayan N, Pharoah P, Neal DE, et al. Stage shift in PSA detected prostate cancers: effect modification by Gleason score. J Med Screen. 2009;16:98-101.
3. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-923.
4. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
5. Lochter A, Navre M, Werb Z, Bissell MJ. alpha1 and alpha2 integrins mediate invasive activity of mouse mammary carcinoma cells through regulation of stromelysin-1 expression. Mol Biol Cell. 1999;10:271-282. (Pubitemid 29156472)
6. Kirkland SC, Ying H. Alpha2beta1 integrin regulates lineage commitment in multipotent human colorectal cancer cells. J Biol Chem. 2008;283:27612-27619.
7. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+α2β1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007;67:6796-6805. (Pubitemid 47105527)
8. Kostenuik PJ, Sanchez-Sweatman O, Orr FW, Singh G. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis. 1996;14:19-26. (Pubitemid 26008958)
9. Slack-Davis JK, Parsons JT. Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem. 2004;91:41-46.
10. Chung LWK, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005;173:10-20. (Pubitemid 39627663)
11. Hall CL, Dai J, van Golen KL, Keller ET, Long MW, Type I collagen receptor (α2β1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res. 2006;66:8648-8654. (Pubitemid 44449180)
12. Kiefer JA, Farach-Carson MC. Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: implications for enhanced growth in the bone microenvironment. Matrix Biol. 2001;20:429-437. (Pubitemid 33016380)
13. Huang CW, Li Z, Cai H, Shahinian T, Conti PS. Biological stability evaluation of the α2β1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide. Bioconjug Chem. 2011;22:256-263.
14. Huang C, Li Z, Cai H, Chen K, Shahinian T, Conti PS. Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2011;38:1313-1321.
15. 1 integrin-targeted peptide probes for prostate cancer imaging. Mol Imaging. 2011;10:284-294.
16. Rothbard JB, Kreider E, VanDeusen CL, Wright L, Wylie BL, Wender PA. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J Med Chem. 2002;45:3612-3618. (Pubitemid 34856101)
17. Sakai N, Matile S. Anion-mediated transfer of polyarginine across liquid and bilayer membranes. J Am Chem Soc. 2003;125:14348-14356. (Pubitemid 37452373)
18. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem. 2001;276:5836-5840.
19. Futaki S. Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int J Pharm. 2002;245:1-7. (Pubitemid 35299886)
20. Futaki S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev. 2005;57:547-558. (Pubitemid 40255560)
21. Takayama K, Suehisa Y, Fujita T, et al. Oligoarginine-based prodrugs with self-cleavable spacers for caco-2 cell permeation. Chem Pharm Bull (Tokyo). 2008;56:1515-1520.
22. Futaki S, Goto S, Suzuki T, Nakase I, Sugiura Y. Structural variety of membrane permeable peptides. Curr Protein Pept Sci. 2003;4:87-96. (Pubitemid 36834008)
23. Arano Y. Strategies to reduce renal radioactivity levels of antibody fragments. Q J Nucl Med. 1998;42:262-270. (Pubitemid 29052426)
24. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: "Is the Trojan horse too wild to go only to Troy? J Control Release. 2005;109:77-85. (Pubitemid 41737254)
25. Foerg C, Merkle HP. On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci. 2008;97:144-162.
26. Mäe M, Langel Ü. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol. 2006;6:509-514. (Pubitemid 44340662)
27. Vivès E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997;272:16010-16017. (Pubitemid 27265584)
28. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA. 1994;91:664-668. (Pubitemid 24041462)
29. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994;269:10444-10450. (Pubitemid 24198241)
30. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res. 2000;56:318-325.
31. Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med. 1998;4:1449-1452. (Pubitemid 28553472)
32. Sancey L, Garanger E, Foillard S, et al. Clustering and internalization of integrin αvβ3 with a tetrameric RGD-synthetic peptide. Mol Ther. 2009;17:837-843.
33. Baker M, Ntam C, Reese CT, et al. Internalization of near-infrared fluorescent dyes within isolated leukocyte populations. Int J Environ Res Public Health. 2006;3:31-37. (Pubitemid 350002710)
34. Akizawa H, Uehara T, Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev. 2008;60:1319-1328.
35. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55:3825-3834.
36. Boswell CA, Tesar DB, Mukhyala K, Theil F, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21:2153-2163.